Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

First-in-Class Masked Antibody Therapeutic Effective in Fighting Pancreatic Tumor Models

By BiotechDaily International staff writers
Posted on 13 Nov 2013
In research conducted with multiple preclinical models, the data indicate that a new masked antibody therapeutic has been shown to be effective in fighting pancreatic cancer models as both a single agent and in combination with gemcitabine, a currently available antimetabolite drug approved by the US Food and Drug Administration (FDA) to treat pancreatic and other cancers.

Furthermore, the data show that the agent is locally activated in the tumor microenvironment and it spares systemic side effects, such as skin toxicity associated with systemically blocking Notch pathway signaling.

CytomX Therapeutics (South San Francisco, CA, USA), a Probody therapeutics company, recently presented data demonstrating preclinical proof-of-concept of the company’s Jagged Probody blocking Jagged-dependent Notch signaling for the treatment of cancer. These data were presented for the first time at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 19-23, 2013, in Boston (MA, USA).

“The Notch pathway is centrally implicated in tumor biology and is involved in the progression of a number of cancers, including pancreatic cancer, triple negative breast cancer, and multiple myeloma,” stated Henry Lowman, PhD, chief scientific officer of CytomX and senior author of the poster. “Our anti-Jagged Probody represents a novel approach to targeting the Notch signaling pathway, and our data establish preclinical proof-of-concept that selective activation of CTX-033 in the tumor microenvironment results in robust efficacy with an acceptable therapeutic index.”

Probodies are masked antibodies that remain inert in healthy tissue but are activated or “unmasked” in the disease microenvironment. CytomX is developing a novel, first-in-class Probody program that blocks Notch signaling by both the Jagged-1 and Jagged-2 ligands locally in the tumor microenvironment.

“Following our recent publication on the Probody platform in Science Translational Medicine, these data provide further validation of our unique and highly differentiated Probody approach,” said Sean McCarthy, D.Phil., chief executive officer of CytomX. “Our Jagged Probody program showcases the value of the Probody platform in targeting a pathway that has been challenging with traditional antibodies because of healthy tissue toxicities, and we look forward to advancing this novel concept towards clinical testing.”

CytomX’s Probody platform represents a disruptive approach to discovering and developing the next-generation of antibody therapeutics and is enabling the development of a diversified pipeline in major unmet medical needs including cancer and inflammation. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. This breakthrough selectivity allows CytomX to drug previously undruggable antibody targets, unlock new therapeutic targets for antibody-drug conjugates (ADCs), and focus activity in the tumor microenvironment, thereby redefining the landscape for therapeutic antibodies.

Related Links:

CytomX Therapeutics



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.